Association/NN
of/IN
the/DT
Human/JJ
IL-28RAGene/NN
Polymorphisms/NNS
in/IN
a/DT
./.
====================
Korean/NN
Population/NN
with/IN
Asthma/NN
====================
IL-28RA/NN
is/VBZ
one/CD
of/IN
the/DT
important/JJ
candidate/NN
genes/NNS
for/IN
====================
complex/NN
trait/VBP
of/IN
genetic/JJ
diseases/NNS
,/,
but/CC
there/EX
are/VBP
only/RB
a/DT
few/JJ
published/VBN
results/NNS
for/IN
this/DT
gene/NN
./.
====================
Previously/RB
,/,
we/PRP
identified/VBD
eighteen/CD
SNPs/NNS
and/CC
two/CD
variation/NN
sites/NNS
in/IN
the/DT
entire/JJ
coding/VBG
regions/NNS
of/IN
IL-28RA/NN
including/VBG
promoter/NN
regions/NNS
,/,
and/CC
suggested/VBD
that/IN
the/DT
g.32349G/NN
>/JJR
A/DT
polymorphism/NN
of/IN
IL-28RA/NN
might/MD
be/VB
associated/VBN
with/IN
susceptibility/NN
to/TO
allergic/JJ
rhinitis/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
chose/VBP
seven/CD
SNPs/NNS
(/(
g.-1193A/NN
>/JJR
C/NN
,/,
g.-30OT/NN
,/,
g.17654OT/NN
,/,
g.27798A/JJ
>/JJR
G/NN
,/,
g.31265OT/NN
,/,
g.31911OT/NN
and/CC
g.32349G/NN
>/JJR
A/DT
)/)
of/IN
IL-28RA/NN
,/,
and/CC
attempted/VBD
to/TO
find/VB
out/IN
whether/IN
these/DT
polymorphisms/NNS
were/VBD
furtherassodated/VBN
with/IN
genetic/JJ
predisposition/NN
of/IN
asthma/NN
./.
====================
We/PRP
analyzed/VBD
the/DT
genotype/NN
and/CC
allele/NN
frequencies/NNS
of/IN
IL-28RA/NN
polymorphisms/NNS
between/IN
the/DT
asthma/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
./.
====================
We/PRP
also/RB
investigated/VBD
the/DT
frequencies/NNS
of/IN
haplotype/JJ
constructed/VBN
by/IN
these/DT
SNPs/NNS
between/IN
asthma/NN
patients/NNS
and/CC
controls/VBZ
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
polymorphisms/NNS
of/IN
IL-28RA/NN
gene/NN
were/VBD
not/RB
associated/VBN
with/IN
susceptibility/NN
to/TO
asthma/NN
,/,
and/CC
not/RB
with/IN
IgE/NN
production/NN
and/CC
eosinophil/NN
recruitment/NN
./.
====================
The/DT
haplotype/JJ
frequencies/NNS
by/IN
these/DT
SNPs/NNS
also/RB
not/RB
significantly/RB
associated/VBN
between/IN
the/DT
healthy/JJ
controls/NNS
and/CC
asthma/NN
patients/NNS
./.
====================
This/DT
result/NN
indicates/VBZ
that/IN
the/DT
IL-28RA/NN
polymorphisms/NNS
might/MD
be/VB
not/RB
associated/VBN
withasthma/NN
susceptibility/NN
./.
====================
Asthma/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
common/JJ
multi-complex/JJ
disorders/NNS
that/DT
triggered/VBD
by/IN
genetic/JJ
predisposition/NN
and/CC
environmental/JJ
factors/NNS
(/(
Cookson/NN
,/,
2002/CD
)/)
./.
====================
Unlike/IN
other/JJ
====================
inflammatory/JJ
diseases/NNS
,/,
v/LS
the/DT
asthmatic/JJ
inflammatory/JJ
====================
process/RB
is/VBZ
characterized/VBN
by/IN
the/DT
predominant/JJ
secretion/NN
of/IN
interleukin/NN
(/(
IL/NN
)/)
-4/CD
and/CC
IL-5/NN
by/IN
T-helper/NN
lymphocyte/NN
type/NN
2/CD
(/(
Th2/NN
)/)
and/CC
immunoglobulin/NN
E/NN
(/(
IgE/NN
)/)
synthesis.IgE/NN
mediates/VBZ
early/JJ
and/CC
late/JJ
asthmatic/JJ
responses/NNS
in/IN
an/DT
induction/NN
of/IN
lung/NN
eosinophil/NN
infiltration/NN
and/CC
Th2/NN
cell/NN
cytokine/NN
production/NN
(/(
Coyle/JJ
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
Mast/JJ
cells/NNS
are/VBP
IgE-dependently/RB
activated/VBN
,/,
while/IN
eosinophils/NNS
and/CC
basophils/NNS
are/VBP
recruited/VBN
into/IN
the/DT
site/NN
of/IN
allergic/JJ
reaction/NN
(/(
Daser/NN
et/FW
al./FW
,/,
1995/CD
;/:
O/NN
’/CD
Garra/FW
,/,
1998/CD
)/)
./.
====================
The/DT
accumulation/NN
of/IN
eosinophils/NNS
is/VBZ
an/DT
important/JJ
characteristicfeature/NN
in/IN
the/DT
pathogenesis/NN
of/IN
asthma/NN
,/,
because/IN
it/PRP
accompanied/VBD
by/IN
inflammation/NN
within/IN
the/DT
bronchial/JJ
wall/NN
(/(
Humbles/NNS
et/FW
al./FW
,/,
1997/CD
)/)
./.
====================
Cytokines/NNS
are/VBP
multifunctional/JJ
proteins/NNS
that/WDT
mediate/VBP
many/JJ
of/IN
responses/NNS
of/IN
innate/JJ
and/CC
adaptive/JJ
immunities/NNS
./.
====================
They/PRP
are/VBP
produced/VBN
in/IN
response/NN
to/TO
microbes/NNS
,/,
antigens/NNS
,/,
and/CC
other/JJ
cytokines/NNS
and/CC
stimulatediverse/JJ
responses/NNS
of/IN
cells/NNS
involved/VBN
in/IN
immunity/NN
and/CC
inflammation/NN
./.
====================
They/PRP
act/VBP
on/IN
target/NN
cells/NNS
by/IN
binding/VBG
to/TO
specific/JJ
cytokine/NN
receptor/NN
,/,
initiating/VBG
signal/NN
transduction/NN
and/CC
second/JJ
signal/NN
pathways/NNS
within/IN
the/DT
target/NN
cell/NN
(/(
Hibi/NNP
and/CC
Hirano/JJ
,/,
1998/CD
;/:
Onishi/NNP
et/FW
al./FW
,/,
1998/CD
;/:
O/NNP
’/CD
Shea/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
The/DT
SNPs/NNS
of/IN
many/JJ
cytokines/NNS
and/CC
their/PRP$
receptor/NN
genes/NNS
,/,
such/JJ
as/IN
IL-10/NN
,/,
IL-12/NN
,/,
IFNy/JJ
,/,
RANTES/NN
,/,
CCR2/NN
and/CC
CCR5/NN
,/,
are/VBP
identified/VBN
(/(
Gibson/NNP
eta/NN
!/NNP
./.
,/,
2001/CD
;/:
Hall/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Iwasaki/NNP
et/FW
al./FW
,/,
2001/CD
)/)
and/CC
indicate/VBP
that/IN
the/DT
polymorphisms/NNS
are/VBP
associated/VBN
with/IN
immune/JJ
disorders/NNS
(/(
Fryer/JJ
et/FW
al./FW
,/,
2000/CD
;/:
Nakao/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
We/PRP
previously/RB
reported/VBN
that/IN
the/DT
polymorphisms/NNS
of/IN
eotaxin/NN
gene/NN
family/NN
(/(
eotaxin/NN
,/,
eotaxin-2/NN
and/CC
eotaxin-3/NN
)/)
and/CC
the/DT
exon/NN
4/CD
variation/NN
of/IN
Tim-1/NN
are/VBP
associated/VBN
with/IN
asthma/NN
in/IN
Korean/JJ
population/NN
(/(
Chae/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Chae/NNP
etal./FW
,/,
2004/CD
)/)
./.
====================
The/DT
new/JJ
cytokine/NN
family/NN
consisting/VBG
of/IN
interleukin/NN
28A/CD
(/(
IL-28A/NN
;/:
also/RB
designated/VBN
as/IN
IFN-y2/JJ
)/)
,/,
IL-28B/NN
(/(
IFN-y3/NN
)/)
and/CC
IL-29/NN
(/(
lFN-y1/NN
)/)
and/CC
a/DT
component/JJ
of/IN
their/PRP$
receptors/NNS
,/,
1L-28RA/NN
(/(
IFN-yR1/NN
)/)
,/,
are/VBP
identified/VBN
from/IN
the/DT
human/JJ
genomic/JJ
sequence/NN
(/(
Dumoutier/RBR
et/FW
al./FW
,/,
2003/CD
;/:
Kotenko/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Sheppard/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
They/PRP
are/VBP
distantly/RB
related/JJ
to/TO
type/NN
I/CD
interferons/NNS
(/(
IFNs/NNS
)/)
and/CC
the/DT
IL-10/NN
family/NN
,/,
and/CC
induced/VBD
by/IN
viral/JJ
infection/NN
and/CC
show/VBP
antiviral/JJ
activity/NN
(/(
Sheppard/NNP
etal./FW
,/,
2003/CD
;/:
Kotenko/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
However/RB
,/,
IL-28/NN
and/CC
IL-29/NN
====================
interact/VBP
with/IN
a/DT
heterodimeric/JJ
class/NN
II/CD
cytokine/NN
receptor/NN
that/WDT
consist/VBP
of/IN
IL-10/NN
receptor/NN
p/NN
(/(
IL-1OR0/NN
)/)
and/CC
an/DT
orphan/NN
class/NN
II/CD
receptor/NN
chain/NN
,/,
designated/VBN
IL-28RA/NN
./.
====================
Recently/RB
,/,
Dumoutier/IN
and/CC
co-workers/NNS
suggested/VBD
that/IN
IL-29/NN
induced/VBD
STAT2/NN
tyrosine/NN
phosphorylation/NN
is/VBZ
mediated/VBN
through/IN
tyrosines/NNS
343/CD
and/CC
517/CD
of/IN
the/DT
IL-28RAand/NN
these/DT
two/CD
tyrosines/NNS
are/VBP
also/RB
responsible/JJ
for/IN
antiviral/JJ
and/CC
anti-/JJ
proliferative/JJ
activities/NNS
of/IN
IL-29/NN
./.
====================
In/IN
contrast/NN
,/,
STAT4/NN
phosphorylation/NN
is/VBZ
independent/JJ
from/IN
IL-28RA/NN
tyrosine/NN
residues/NNS
(/(
Dumoutier/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
IL-28RAgenes/NNS
are/VBP
located/JJ
on/IN
the/DT
chromosomal/JJ
region/NN
1/CD
p36.11/NN
and/CC
have/VBP
seven/CD
exons/NNS
./.
====================
More/RBR
recently/RB
,/,
we/PRP
identified/VBD
eighteen/CD
SNPs/NNS
and/CC
two/CD
variation/NN
sites/NNS
in/IN
human/JJ
IL-28RA/NN
gene/NN
and/CC
reported/VBD
that/IN
the/DT
g.32349G/NN
>/JJR
A/DT
polymorphism/NN
of/IN
IL-28RA/NN
might/MD
be/VB
associated/VBN
with/IN
susceptibility/NN
to/TO
allergic/JJ
rhinitis/NN
(/(
Chae/NNP
et/FW
a/./FW
,/,
2006/CD
)/)
./.
====================
In/IN
an/DT
attempt/NN
to/TO
better/RBR
understand/VB
the/DT
genetic/JJ
influences/VBZ
of/IN
IL-28RA/NN
on/IN
allergic/JJ
disease/NN
such/JJ
as/IN
asthma/NN
,/,
we/PRP
analyzed/VBD
the/DT
genotype/NN
frequencies/NNS
of/IN
the/DT
SNPs/NNS
in/IN
IL-28RA/NN
in/IN
the/DT
genomic/JJ
DNAs/NNS
isolated/VBN
from/IN
asthma/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
to/TO
determine/VB
whether/IN
these/DT
IL-28RA/NN
SNPs/NNS
are/VBP
associated/VBN
with/IN
asthma/NN
susceptibility/NN
./.
====================
We/PRP
further/RB
investigated/VBD
the/DT
relationships/NNS
among/IN
these/DT
polymorphisms/NNS
to/TO
IgE/NN
levels/NNS
and/CC
peripheral/JJ
blood/NN
eosinophil/NN
counts/NNS
in/IN
asthma/NN
patients/NNS
./.
====================
On/IN
the/DT
basis/NN
of/IN
approval/JJ
and/CC
informed/VBN
consent/NN
from/IN
the/DT
review/NN
board/IN
of/IN
School/NN
of/IN
Medicine/NN
,/,
Wonkwang/NNP
University/NN
,/,
blood/NN
samples/NNS
were/VBD
obtained/VBN
from/IN
280/CD
asthma/NN
patients/NNS
(/(
146/CD
males/NNS
and/CC
134/CD
females/NNS
)/)
and/CC
559/CD
healthy/JJ
non-asthma/NN
controls/NNS
(/(
346/CD
males/NNS
and/CC
213/CD
females/NNS
)/)
./.
====================
The/DT
mean/JJ
ages/NNS
of/IN
asthma/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
were/VBD
about/RB
50.5/CD
and/CC
40.8/CD
years/NNS
respectively/RB
./.
====================
Genomic/JJ
DNA/NN
was/VBD
extracted/VBN
from/IN
leukocytes/NNS
of/IN
peripheral/JJ
blood/NN
by/IN
a/DT
standard/JJ
phenol-/NN
chloroform/NN
method/NN
or/CC
by/IN
Genomic/JJ
DNA/NN
Extraction/NN
kit/NN
(/(
iNtRON/NN
Biotechnology/NN
,/,
Korea/NN
)/)
according/VBG
to/TO
manufacturer/VB
’/CD
s/NNS
directions/NNS
./.
====================
The/DT
asthma/NN
(/(
atopic/JJ
and/CC
non-atopic/JJ
)/)
patients/NNS
were/VBD
recruited/VBN
from/IN
our/PRP$
outpatient/JJ
clinic/NN
at/IN
Chonbuk/NN
National/JJ
University/NN
Hospital/JJ
./.
====================
Asthma/NN
was/VBD
diagnosed/VBN
in/IN
reference/NN
to/TO
the/DT
criteria/NNS
of/IN
the/DT
American/NN
Thoracic/JJ
Society/NN
(/(
American/NN
Thoracic/JJ
Society/NN
,/,
1987/CD
)/)
./.
====================
The/DT
healthy/JJ
controls/NNS
were/VBD
recruited/VBN
from/IN
the/DT
general/JJ
population/NN
and/CC
had/VBD
undergone/NN
a/DT
comprehensive/JJ
medical/JJ
screening/NN
at/IN
the/DT
Wonkwang/NNP
University/NN
Hospital/JJ
./.
====================
All/DT
subjects/NNS
employed/VBN
in/IN
this/DT
study/NN
were/VBD
Korean/JJ
who/WP
is/VBZ
living/JJ
in/IN
the/DT
same/JJ
area/NN
./.
====================
Blood/NN
eosinophil/NN
counts/NNS
and/CC
total/JJ
serum/NN
IgE/NN
levels/NNS
in/IN
asthma/NN
patients/NNS
were/VBD
measured/VBN
,/,
at/IN
the/DT
Department/JJ
of/IN
Hematology/NN
of/IN
Chonbuk/NN
National/JJ
University/NN
Hospital/JJ
,/,
using/VBG
a/DT
Coulter/NN
GenSTM/NN
Hematology/NN
Analyzer/NN
(/(
Florida/NN
,/,
USA/NNP
)/)
and/CC
Roche/NNP
====================
COBAS-COREII/NN
(/(
Roche/NNP
Diagnostics/NNS
,/,
Basal/JJ
,/,
Switzerland/CC
)/)
,/,
respectively/RB
./.
====================
The/DT
entire/JJ
coding/VBG
regions/NNS
of/IN
IL-28RA/NN
including/VBG
-2.0/CD
kb/NN
promoter/NN
regions/NNS
were/VBD
partially/RB
amplified/VBN
by/IN
PCR/NN
using/VBG
the/DT
six/CD
primer/NN
pairs/NNS
,/,
and/CC
PCR/NN
reactions/NNS
were/VBD
prepared/VBN
by/IN
previously/RB
described/VBN
condition/NN
(/(
Chae/NNP
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
Amplification/NN
was/VBD
carried/VBN
out/RP
in/IN
a/DT
GeneAmp/JJ
PCR/NN
system/NN
9700/CD
thermocycler/DT
(/(
PE/NN
Applied/VBN
Biosystem/NNP
,/,
USA/NNP
)/)
at/IN
94°C/NN
for/IN
2/CD
minutes/NNS
,/,
followed/VBN
by/IN
10/CD
cycles/NNS
at/IN
94°C/NN
for/IN
10/CD
seconds/NNS
,/,
68°C/NNP
or/CC
45/CD
seconds/VBZ
(/(
2/CD
minutes/NNS
for/IN
promoter/NN
and/CC
exon/NN
1/CD
region/NN
,/,
and/CC
4/CD
minutes/NNS
for/IN
exon/NN
7/CD
and/CC
3/CD
’/NNP
UTR/NN
region/NN
)/)
,/,
and/CC
68°C/JJ
for/IN
10/CD
minutes/NNS
./.
====================
Then/RB
20/CD
cycles/NNS
at/IN
94°C/NN
for/IN
10/CD
seconds/NNS
,/,
68°C/NN
for/IN
45/CD
seconds/NNS
and/CC
68°C/NN
or/CC
10/CD
minutes/NNS
(/(
with/IN
10/CD
seconds/NNS
incremental/JJ
increases/VBZ
per/IN
cycle/NN
)/)
were/VBD
followed/VBN
by/IN
a/DT
final/JJ
extension/NN
at/IN
68°C/NN
for/IN
7/CD
minutes/NNS
./.
====================
Genotyping/VBG
for/IN
g.-1193A/NN
>/JJR
C/NN
,/,
g.-30C/NN
>/JJR
T/NN
,/,
g.17654C/NN
>/JJR
T/NN
,/,
g.27798A/JJ
>/JJR
G/NN
,/,
g.31265C/NN
>/JJR
T/NN
,/,
g.31911C/NN
>/JJR
Tar/JJ
}/CD
d/FW
g.32349G/NN
>/JJR
A/DT
in/IN
the/DT
IL-28RA/NN
gene/NN
was/VBD
performed/VBN
by/IN
single-base/JJ
extension/NN
(/(
SBE/NNS
)/)
method/NN
(/(
Chae/NNP
et/FW
al./FW
,/,
2006/CD
)/)
using/VBG
the/DT
ABI/NN
Prism®/NN
SNaPshot™/NN
Multiplex/JJ
kit/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
./.
====================
The/DT
PCR/NN
products/NNS
purified/VBN
by/IN
PCR/NN
purification/NN
kit/NN
(/(
Millipore/RBR
,/,
USA/NN
)/)
were/VBD
used/VBN
as/IN
the/DT
template/NN
DNA/NN
for/IN
genotyping/VBG
./.
====================
The/DT
SBE/NNS
reaction/NN
mix/NN
was/VBD
prepared/VBN
according/VBG
to/TO
previously/RB
described/VBN
method/NN
(/(
Chae/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
The/DT
primer/NN
extension/NN
reaction/NN
was/VBD
performed/VBN
at/IN
96°C/NN
for/IN
1/CD
minute/JJ
,/,
followed/VBN
by/IN
25/CD
cycles/NNS
at/IN
96°C/NN
for/IN
10/CD
seconds/NNS
,/,
55°C/NN
for/IN
40/CD
seconds/NNS
,/,
and/CC
60°C/NN
for/IN
30/CD
seconds/NNS
./.
====================
To/TO
clean/JJ
up/IN
the/DT
primer/NN
extension/NN
reaction/NN
,/,
1.5/CD
unit/NN
of/IN
CIP/NN
(/(
Promega/NNP
)/)
was/VBD
added/VBN
to/TO
the/DT
reaction/NN
mixture/NN
,/,
and/CC
the/DT
mixture/NN
was/VBD
incubated/VBN
at/IN
37°C/NN
for/IN
90/CD
minutes/NNS
,/,
followed/VBN
by/IN
15/CD
minutes/NNS
at/IN
72°C/JJ
for/IN
purposes/NNS
of/IN
enzyme/NN
inactivation/NN
./.
====================
The/DT
purified/VBN
extension/NN
products/NNS
were/VBD
added/VBN
to/TO
Hi-Di/JJ
formamide/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
according/VBG
to/TO
the/DT
recommendations/NNS
of/IN
the/DT
manufacturer/NN
./.
====================
The/DT
mixture/NN
was/VBD
incubated/VBN
at/IN
95°C/NN
for/IN
5/CD
minutes/NNS
,/,
followed/VBN
by/IN
5/CD
minutes/NNS
on/IN
ice/RB
,/,
and/CC
then/RB
electrophoresis/NN
was/VBD
performed/VBN
,/,
using/VBG
the/DT
ABI/NN
Prism/NN
3100/CD
Genetic/JJ
Analyzer/NN
./.
====================
The/DT
results/NNS
were/VBD
analyzed/VBN
using/VBG
the/DT
ABI/NN
Prism/NN
GeneScan/NN
and/CC
Genotyper/NN
software/JJ
(/(
Applied/VBN
Biosystems/NNS
)/)
./.
====================
The/DT
allergic/JJ
rhinitis/NN
patients/NNS
and/CC
non-allergic/JJ
rhinitis/NN
controls/NNS
were/VBD
compared/VBN
using/VBG
case-control/JJ
association/NN
analyses/NNS
./.
====================
The/DT
x/NN
2/CD
tests/NNS
were/VBD
used/VBN
to/TO
estimate/VB
the/DT
Hardy-/JJ
Weinberg/NN
equilibrium/NN
(/(
HWE/NN
)/)
./.
====================
Logistic/JJ
regression/NN
analyses/NNS
====================
were/VBD
used/VBN
to/TO
calculate/VB
odds/NNS
ratios/NNS
(/(
95/CD
%/NN
confidence/NN
interval/JJ
)/)
for/IN
SNP/NN
sites/NNS
./.
====================
Linkage/JJ
Disequilibrium/NN
(/(
LD/NN
)/)
analyses/NNS
by/IN
pair-wise/JJ
comparison/NN
of/IN
biallelic/JJ
loci/NNS
and/CC
the/DT
haplotype/JJ
frequencies/NNS
of/IN
IL-28RA/NN
for/IN
multiple/JJ
loci/NNS
were/VBD
estimated/VBN
using/VBG
the/DT
expectation/NN
maximization/NN
(/(
EM/NN
)/)
algorithm/NN
with/IN
SNPAlyze/NN
software/RB
(/(
DYNACOM/NN
,/,
Japan/NNP
)/)
./.
====================
The/DT
haplotype/JJ
analyses/NNS
of/IN
IL-28RA/NN
SNPs/NNS
between/IN
asthma/NN
patients/NNS
and/CC
control/NN
were/VBD
performed/VBN
by/IN
Permutation/NN
test/NN
./.
====================
A/DT
P-value/JJ
of/IN
less/RBR
than/IN
0.05/CD
was/VBD
considered/VBN
to/TO
indicate/VB
statistical/JJ
significance/NN
./.
====================
In/IN
response/NN
to/TO
different/JJ
cytokine/NN
profiles/NNS
,/,
T/NN
helper/NN
cells/NNS
are/VBP
classified/VBN
into/IN
Th1/NN
and/CC
Th2/NN
subsets/NNS
./.
====================
Th1/NN
cells/NNS
secrete/VBP
cytokines/NNS
(/(
including/VBG
IFN-y/JJ
,/,
IL-2/NN
and/CC
TNF-p/NN
)/)
and/CC
they/PRP
join/VBP
in/IN
the/DT
elimination/NN
of/IN
intracellular/JJ
pathogens/NNS
./.
====================
On/IN
the/DT
other/JJ
====================
hand/NN
,/,
Th2/NN
cells/NNS
produce/VBP
IL-4/NN
,/,
IL-5/NN
,/,
IL-10/NN
and/CC
IL-13/NN
./.
====================
Eventually/RB
,/,
they/PRP
promote/VBP
antibody/NN
production/NN
and/CC
control/NN
extracellular/JJ
pathogens/NNS
(/(
Ho/NN
and/CC
Glimcher/NN
,/,
2002/CD
)/)
./.
====================
Th1/Th2/NN
balance/NN
is/VBZ
very/RB
important/JJ
in/IN
maintaining/VBG
the/DT
healthy/JJ
state/NN
of/IN
body/NN
./.
====================
When/WRB
the/DT
balance/NN
is/VBZ
altered/JJ
,/,
some/DT
disorders/NNS
(/(
such/JJ
as/IN
asthma/NN
and/CC
RA/NN
)/)
would/MD
occur/VB
./.
====================
Th1/NN
and/CC
Th2/NN
cells/NNS
can/MD
mutually/RB
antagonize/VBP
the/DT
differentiation/NN
of/IN
the/DT
counterpart/NN
subset/NN
(/(
Lafaille/NN
etal./FW
,/,
1997/CD
)/)
./.
====================
IL-28RA/NN
is/VBZ
recently/RB
identified/VBN
from/IN
the/DT
human/JJ
genomic/JJ
sequence/NN
as/IN
a/DT
component/NN
of/IN
their/PRP$
receptors/NNS
for/IN
the/DT
new/JJ
cytokine/NN
consisting/VBG
of/IN
IL-28A/NN
,/,
IL-28B/NN
and/CC
IL-29/NN
(/(
Sheppard/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Kotenko/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Although/IN
IL-28RA/NN
is/VBZ
one/CD
of/IN
the/DT
important/JJ
candidate/NN
genes/NNS
for/IN
complex/NN
trait/VBP
of/IN
genetic/JJ
diseases/NNS
,/,
there/EX
are/VBP
only/RB
a/DT
few/JJ
published/VBN
results/NNS
for/IN
this/DT
gene/NN
./.
====================
Previously/RB
,/,
we/PRP
identified/VBD
eighteen/CD
SNPs/NNS
and/CC
two/CD
variation/NN
sites/NNS
in/IN
the/DT
entire/JJ
coding/VBG
regions/NNS
of/IN
IL-28RA/NN
including/VBG
promoter/NN
regions/NNS
,/,
and/CC
suggested/VBD
that/IN
the/DT
g.32349G/NN
>/JJR
A/DT
polymorphism/NN
of/IN
IL-28RA/NN
====================
might/MD
be/VB
associated/VBN
with/IN
susceptibility/NN
to/TO
allergic/JJ
rhinitis/NN
,/,
but/CC
seems/VBZ
to/TO
have/VB
no/DT
relationship/NN
with/IN
serum/NN
total/JJ
IgE/NN
levels/NNS
./.
====================
The/DT
haplotype/JJ
frequencies/NNS
by/IN
these/DT
SNPs/NNS
also/RB
show/VBP
significant/JJ
association/NN
between/IN
controls/NNS
and/CC
allergic/JJ
rhinitis/NN
patients/NNS
./.
====================
In/IN
our/PRP$
present/JJ
study/NN
,/,
we/PRP
attempted/VBD
to/TO
find/VB
out/IN
whether/IN
these/DT
polymorphisms/NNS
of/IN
IL-28RA/NN
were/VBD
further/RB
associated/VBN
with/IN
genetic/JJ
predisposition/NN
of/IN
another/DT
allergic/JJ
disease/NN
such/JJ
as/IN
asthma/NN
./.
====================
We/PRP
analyzed/VBD
the/DT
genotype/NN
and/CC
allele/NN
frequencies/NNS
of/IN
IL-28RA/NN
polymorphisms/NNS
between/IN
the/DT
asthma/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
./.
====================
The/DT
genotype/NN
frequencies/NNS
of/IN
all/DT
loci/NNS
were/VBD
in/IN
HWE/NN
(/(
P/NN
>/JJR
0.05/CD
,/,
data/NNS
not/RB
shown/VBN
)/)
./.
====================
The/DT
genotype/NN
and/CC
allele/NN
frequencies/NNS
of/IN
polymorphisms/NNS
in/IN
asthma/NN
patients/NNS
were/VBD
not/RB
significantly/RB
different/JJ
from/IN
those/DT
====================
in/IN
the/DT
controls/NNS
group/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
This/DT
result/NN
suggests/VBZ
the/DT
polymorphisms/NNS
of/IN
IL-28RA/NN
are/VBP
not/RB
associated/VBN
with/IN
susceptibility/NN
to/TO
asthma/NN
./.
====================
We/PRP
further/RB
analyzed/VBD
the/DT
genotype/NN
and/CC
allele/NN
frequencies/NNS
of/IN
atopic/JJ
asthma/NN
,/,
non-atopic/JJ
asthma/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
./.
====================
In/IN
both/DT
atopic/JJ
and/CC
non-atopic/JJ
asthma/NN
patients/NNS
,/,
the/DT
genotype/NN
and/CC
allele/NN
frequencies/NNS
of/IN
IL-28RA/NN
polymorphism/NN
,/,
were/VBD
not/RB
significantly/RB
different/JJ
from/IN
the/DT
frequencies/NNS
of/IN
healthy/JJ
control/JJ
group/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
This/DT
result/NN
indicates/VBZ
that/IN
the/DT
polymorphism/NN
of/IN
IL-28RA/NN
might/MD
be/VB
not/RB
associated/VBN
with/IN
susceptibility/NN
of/IN
atopic/JJ
disease/NN
./.
====================
Eosinophil/NN
is/VBZ
accumulated/VBN
in/IN
high/JJ
numbers/NNS
in/IN
the/DT
lungs/NNS
of/IN
asthmatic/JJ
patients/NNS
and/CC
is/VBZ
believed/VBN
to/TO
be/VB
essential/JJ
in/IN
phagocytosis/NN
as/IN
well/RB
as/IN
in/IN
allergic/JJ
and/CC
inflammatory/JJ
reactions/NNS
of/IN
asthma/NN
./.
====================
Therefore/RB
,/,
the/DT
number/NN
of/IN
accumulated/VBN
eosinophils/NNS
====================
within/IN
the/DT
bronchial/JJ
wall/NN
is/VBZ
a/DT
characteristic/JJ
feature/NN
of/IN
asthma/NN
(/(
Humbles/NNS
etal./FW
,/,
1997/CD
)/)
./.
====================
At/IN
least/JJS
,/,
a/DT
dozen/JJ
of/IN
polymorphic/JJ
genes/NNS
have/VBP
been/VBN
estimated/VBN
that/DT
regulate/VBP
asthma/NN
by/IN
controlling/VBG
the/DT
inflammatory/JJ
response/NN
,/,
total/JJ
serum/NN
immunoglobulin/NN
E/NN
(/(
IgE/NN
)/)
,/,
cytokines/NNS
and/CC
chemokines/NNS
(/(
Cookson/NN
,/,
1999/CD
)/)
./.
====================
However/RB
,/,
our/PRP$
results/NNS
reveal/VBP
the/DT
polymor/NN
phisms/NNS
of/IN
IL-28RA/NN
gene/NN
in/IN
asthma/NN
patients/NNS
are/VBP
not/RB
closely/RB
associated/VBN
with/IN
the/DT
level/NN
of/IN
total/JJ
serum/NN
IgE/NN
,/,
the/DT
peripheral/JJ
blood/NN
eosinophil/NN
count/NN
,/,
FVC/NN
and/CC
FEVi/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
We/PRP
also/RB
calculated/VBN
the/DT
haplotype/NN
fre­/JJ
quencies/NNS
among/IN
g.-30C/NN
>/JJR
T/NN
,/,
g.17654C/NN
>/JJR
T/NN
,/,
g.27798A/NN
>/JJR
G/NN
and/CC
g.32349G/NN
>/JJR
A/DT
in/IN
both/DT
healthy/JJ
controls/NNS
and/CC
asthma/NN
====================
patients/NNS
./.
====================
While/IN
the/DT
most/JJS
major/JJ
haplotype/NN
(/(
20.3/CD
%/NN
of/IN
distributions/NNS
)/)
in/IN
healthy/JJ
control/JJ
was/VBD
TCGG/NN
,/,
the/DT
most/JJS
major/JJ
haplotype/NN
(/(
22.5/CD
%/NN
of/IN
distributions/NNS
)/)
was/VBD
TCAG/NN
in/IN
asthma/NN
patients/NNS
(/(
Table/JJ
4/CD
)/)
./.
====================
The/DT
distribution/NN
of/IN
haplotype/JJ
TCAG/NN
and/CC
TTAG/NN
were/VBD
significantly/RB
different/JJ
between/IN
the/DT
controls/NNS
and/CC
asthma/NN
patients/NNS
(/(
P=0.039/NN
and/CC
P/NN
=/JJ
0.023/CD
,/,
respectively/RB
)/)
./.
====================
But/CC
the/DT
frequency/NN
of/IN
haplotype/JJ
TTAG/NN
was/VBD
low/JJ
in/IN
both/DT
group/NN
,/,
and/CC
the/DT
haplotype/NN
TCAG/NN
corrected/VBD
by/IN
bonferroni/NN
correction/NN
also/RB
not/RB
significantly/RB
associated/VBN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
the/DT
haplotype/NN
frequencies/NNS
by/IN
these/DT
SNPs/NNS
also/RB
not/RB
significantly/RB
associated/VBN
between/IN
the/DT
healthy/JJ
controls/NNS
and/CC
====================
asthma/NN
patients/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
our/PRP$
results/NNS
suggest/VBP
that/IN
the/DT
polymorphisms/NNS
of/IN
IL-28RA/NN
gene/NN
were/VBD
not/RB
associated/VBN
with/IN
susceptibility/NN
to/TO
asthma/NN
,/,
and/CC
not/RB
with/IN
IgE/NN
production/NN
and/CC
eosinophil/NN
recruitment/NN
./.
====================
The/DT
haplotype/JJ
frequencies/NNS
by/IN
these/DT
SNPs/NNS
also/RB
not/RB
significantly/RB
associated/VBN
between/IN
controls/NNS
and/CC
asthmapatients/NNS
./.
====================
Our/PRP$
study/NN
is/VBZ
the/DT
first/JJ
analysis/NN
about/RB
IL-28RA/NN
SNPs/NNS
in/IN
asthma/NN
,/,
and/CC
may/MD
contribute/VB
to/TO
the/DT
future/JJ
study/NN
on/IN
the/DT
IL-28RA/NN
functions/NNS
and/CC
association/NN
studies/NNS
with/IN
other/JJ
allergic/JJ
,/,
atopic/JJ
or/CC
infectious/JJ
disease/NN
./.
====================
